findmyKOL
Clinical trialNCT05236621UnknownPhase 3Interventional

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

SponsorQilu Pharmaceutical Co., Ltd.Enrollment85Multiple MyelomaRecurrent or Refractory
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Beijing Chaoyang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Shengjing Hospital Affiliated To China Medical University

    Beijing, Beijing Municipality, China

  • Foshan First People'S Hospital

    Foshan, Guangdong, China

  • Guangzhou First People'S Hospital

    Guangzhou, Guangdong, China

  • the First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • the First Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Guizhou Provincial People'S Hospital

    Guiyang, Guizhou, China

  • the Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • the Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Henan Tumor Hospital

    Zhengzhou, Henan, China

  • the First Affiliated Hospital of Nanhua University

    Hengyang, Hunan, China

  • Shandong University Qilu Hospital

    Jinan, Shandong, China

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Weifang People'S Hospital

    Weifang, Shandong, China

  • Weihai Central Hospital

    Weihai, Shandong, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

  • the Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Second Affiliated Hospital of Xi 'An Jiaotong University

    Xi’an, Shanxi, China

  • Sichuan Provincial People'S Hospital

    Chengdu, Sichuan, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • the First Affiliated Hospital of Zhejiang University Medical College (hematology)

    Hangzhou, Zhejiang, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Jan 2021
Primary completion
30 Jun 2022
Completion
31 Dec 2023
Last update posted
11 Feb 2022
Registered enrollment
85
Registry id
NCT05236621

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.